{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:12Z","timestamp":1786980072025,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Symptomatic uncomplicated  diverticular disease (SUDD) is a chronic condition frequently characterized by abdominal pain, bloating, and altered bowel habits. While cyclic rifaximin is commonly used for symptom control, interest is growing in the potential role of probiotics. This study aimed to compare the clinical outcomes of patients with SUDD treated with either\n                      <jats:italic>Clostridium butyricum<\/jats:italic>\n                      CBM588\u00ae or cyclic rifaximin over a 12-month period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cross-sectional study included 70 patients with a confirmed diagnosis of SUDD, treated between 2023 and 2024. Patients were divided into two groups based on treatment received: Group A (CBM588\u00ae daily for 12 months) and Group B (cyclic rifaximin 400 mg bid for 7 days per month). Clinical data, symptom profiles, and occurrence of diverticulitis were collected and compared. The primary outcome was the reduction of SUDD-related symptoms, and the secondary outcome was the incidence of acute diverticulitis episodes during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 56 patients completed the 12-month follow-up (31 in Group A, 25 in Group B). No significant difference was observed in the rate of symptomatic flares between groups (19.4% vs. 20%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.7). However, a significantly higher proportion of patients in the CBM588\n                      <jats:sup>\u00ae<\/jats:sup>\n                      group reported adequate symptom relief (77.4% vs. 44%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Improvements in  bloating and tenesmus were more frequent in the CBM588\n                      <jats:sup>\u00ae<\/jats:sup>\n                      group, although not statistically significant. No treatment-related adverse events were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this retrospective comparison,\n                      <jats:italic>Clostridium butyricum<\/jats:italic>\n                      CBM588\n                      <jats:sup>\u00ae<\/jats:sup>\n                      demonstrated similar efficacy to rifaximin in preventing diverticulitis, with a potential advantage in subjective symptom improvement. These findings support further prospective studies to explore the role of CBM588\n                      <jats:sup>\u00ae<\/jats:sup>\n                      in SUDD management.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>Clinicaltrial.gov reference: NCT06852274<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00384-025-05005-6","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T06:49:37Z","timestamp":1760770177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study"],"prefix":"10.1007","volume":"40","author":[{"given":"Riccardo","family":"Urgesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Pagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Fanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Antypas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carla","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Villotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bertuccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Sisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Pierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"issue":"9409","key":"5005_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(04)15597-9","volume":"363","author":"N Stollman","year":"2004","unstructured":"Stollman N, Raskin JB (2004) Diverticular disease of the colon. Lancet 363(9409):631\u2013639","journal-title":"Lancet"},{"key":"5005_CR2","doi-asserted-by":"crossref","unstructured":"Floch MH, Bina I (2004) The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38:S2\u2013S7 3","DOI":"10.1097\/01.mcg.0000124003.07433.ee"},{"key":"5005_CR3","unstructured":"Fialho A, Fialho A, Shuja A (n.d.) Analysis of the epidemiological trends on inpatient diverticulosis admissions in the US: a longitudinal analysis from 1997\u20132018. Cureus 15(2):e34493"},{"issue":"4","key":"5005_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0037-1607464","volume":"31","author":"ST Munie","year":"2018","unstructured":"Munie ST, Nalamati SPM (2018) Epidemiology and pathophysiology of diverticular disease. Clin Colon Rectal Surg 31(4):209\u2013213","journal-title":"Clin Colon Rectal Surg"},{"key":"5005_CR5","doi-asserted-by":"crossref","unstructured":"Cuomo R, Barbara G, Pace F et al (2014) Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol J 2(413\u2013442):11","DOI":"10.1177\/2050640614547068"},{"issue":"Suppl. 4","key":"5005_CR6","first-page":"57","volume":"28","author":"A Tursi","year":"2019","unstructured":"Tursi A, Brandimarte G, Di Mario F et al (2019) International consensus on diverticulosis and diverticular disease. Statements from the 3rd international symposium on diverticular disease. J Gastrointestin Liver Dis 28(Suppl. 4):57\u201365","journal-title":"J Gastrointestin Liver Dis"},{"key":"5005_CR7","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1365-2036.2011.04606.x","volume":"33","author":"M Bianchi","year":"2011","unstructured":"Bianchi M, Festa V, Moretti A et al (2011) Metaanalysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 33:902\u2013910","journal-title":"Aliment Pharmacol Ther"},{"key":"5005_CR8","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/apt.12248","volume":"37","author":"W Kruis","year":"2013","unstructured":"Kruis W, Meier E, Schumacher M et al (2013) German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon\u2013a placebo-controlled study. Aliment Pharmacol Ther 37:680\u2013690","journal-title":"Aliment Pharmacol Ther"},{"key":"5005_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/apt.12463","volume":"38","author":"A Tursi","year":"2013","unstructured":"Tursi A, Brandimarte G, Elisei W et al (2013) Randomised clinical trial: mesalazine and\/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease\u2013a double-blind, randomised, placebocontrolled study. Aliment Pharmacol Ther 38:741\u2013751","journal-title":"Aliment Pharmacol Ther"},{"key":"5005_CR10","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.3748\/wjg.v18.i41.5918","volume":"18","author":"E Lahner","year":"2012","unstructured":"Lahner E, Esposito G, Zullo A et al (2012) Highfiber diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 18:5918\u20135924","journal-title":"World J Gastroenterol"},{"key":"5005_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3748\/wjg.v13.i2.264","volume":"13","author":"A Colecchia","year":"2007","unstructured":"Colecchia A, Vestito A, Pasqui F et al (2007) Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 13:264\u2013269","journal-title":"World J Gastroenterol"},{"key":"5005_CR12","doi-asserted-by":"crossref","unstructured":"Campanini A1, De Conto U, Cavasin F et al (2016) A primary-care interventional model on the diverticular disease: searching for the optimal therapeutic schedule. J Clin Gastroenterol 50(Suppl. 1):S93\u2013S96","DOI":"10.1097\/MCG.0000000000000670"},{"key":"5005_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.02.018","author":"S Bultman","year":"2011","unstructured":"Bultman S et al (2011) The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2011.02.018","journal-title":"Cell Metab"},{"key":"5005_CR14","doi-asserted-by":"crossref","unstructured":"Stoeva MK, Garcia-So J, Justice N, Myers J, Tyagi S, Nemchek M, McMurdie PJ, Kolterman O, Eid J (2021) Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. Gut Microbes 13(1):1\u201328","DOI":"10.1080\/19490976.2021.1907272"},{"issue":"2","key":"5005_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3748\/wjg.v20.i2.376","volume":"20","author":"A Vaiopoulou","year":"2014","unstructured":"Vaiopoulou A, Karamanolis G, Psaltopoulou T, Karatzias G, Gazouli M (2014) Molecular basis of the irritable bowel syndrome. World J Gastroenterol 20(2):376\u2013383","journal-title":"World J Gastroenterol"},{"key":"5005_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00384-013-1807-5","volume":"29","author":"L Krokowicz","year":"2014","unstructured":"Krokowicz L, Stojcev Z, Kaczmarek BF, Kociemba W, Kaczmarek E, Walkowiak J, Krokowicz P, Drews M, Banasiewicz T (2014) Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis\u2014a prospective randomized study. Int J Colorectal Dis 29:387\u2013393","journal-title":"Int J Colorectal Dis"},{"key":"5005_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284820913210","volume":"13","author":"A Lahat","year":"2020","unstructured":"Lahat A, Fidder HH, Ben-Horin S (2020) Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort. Ther Adv Gastroenterol 13:1\u201311. https:\/\/doi.org\/10.1177\/1756284820913210","journal-title":"Ther Adv Gastroenterol"},{"key":"5005_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.15403\/jgld-562","volume":"28","author":"A Tursi","year":"2019","unstructured":"Tursi A, Brandimarte G, Di Mario F, Lanas A, Scarpignato C, Bafutto M, Barbara G, Bassotti G, Binda GA, Biondi A, Biondo S, Cambi\u00e8 G, Cassieri C, Crucitti A, Dumitrascu DL, Elisei W, Escalante R, Hersz\u00e8nyi L, Kruis W, Kupcinskas J, Lahat A, Lecca PG, Maconi G, Malfertheiner P, Mazzari A, Mear\u00ecn F, Milosavljevi\u010b T, Nardone G, Chavez De Oliveira E, Papa A, Papagrigoriadis S, Pera M, Persiani R, Picchio M, Regula J, \u0160timac D, Stollman N, Strate LL, Violi A, Walker MM (2019) International consensus on diverticulosis and diverticular disease. Statements from the 3rd International Symposium on Diverticular Disease. J Gastrointestin Liver Dis 28:57\u201366","journal-title":"J Gastrointestin Liver Dis"},{"key":"5005_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818771305","volume":"11","author":"C Scarpignato","year":"2018","unstructured":"Scarpignato C, Barbara G, Lanas A, Strate LL (2018) Management of colonic diverticular disease in the third millennium: highlights from a symposium held during the United European Gastroenterology Week 2017. Ther Adv Gastroenterol 11:1756284818771305","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"5005_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-020-0153-5","volume":"6","author":"A Tursi","year":"2020","unstructured":"Tursi A, Scarpignato C, Strate LL, Lanas A, Kruis W, Lahat A, Danese S (2020) Colonic diverticular disease. Nat Rev Dis Primers 6(1):20","journal-title":"Nat Rev Dis Primers"},{"key":"5005_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5604\/01.3001.0014.0946","volume":"92","author":"AM Pietrzak","year":"2020","unstructured":"Pietrzak AM, Banasiewicz T, Skoczylas K, Dziki A, Szczepkowski M (2020) Combined therapy: rifaximin-\u03b1 and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease. Pol Przegl Chir 92:22\u201328","journal-title":"Pol Przegl Chir"},{"key":"5005_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jim-2018-000901","volume":"67","author":"F Di Mario","year":"2019","unstructured":"Di Mario F, Miraglia C, Cambi\u00e8 G, Violi A, Nouvenne A, Franceschi M, Brandimarte G, Elisei W, Picchio M, Tursi A (2019) Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J Investig Med 67:767\u2013770","journal-title":"J Investig Med"},{"key":"5005_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5114\/pg.2017.68167","volume":"12","author":"A Moniuszko","year":"2017","unstructured":"Moniuszko A, Rydzewska G (2017) The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a \u201creal-life\u201d study. Gastroenterology Rev 12:145\u2013151","journal-title":"Gastroenterology Rev"},{"issue":"1","key":"5005_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.26355\/eurrev_202101_24410","volume":"25","author":"R De Bastiani","year":"2021","unstructured":"De Bastiani R, Sanna G, Bertolusso L, Casella G, De Polo M, Zamparella M, Cottone C, Tosetti C, Mancuso M, Pirrotta E, Lanzarotto L, Napoli L, De Bastiani M, Disclafani G, Gambaro P, Scoglio R, Belvedere A, Fasulo S, D\u2019Urso M, Benedetto E, Baldi E, Marchesan F, Abagnale G, Turnava L, Salom\u00e8 E, Ingravalle F, Tursi A (2021) General practitioners\u2019 management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic. Eur Rev Med Pharmacol Sci 25(1):423\u2013430. https:\/\/doi.org\/10.26355\/eurrev_202101_24410","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5005_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3109\/00365529609094568","volume":"216","author":"PB Mortensen","year":"1996","unstructured":"Mortensen PB, Clausen MR (1996) Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 216:132\u2013148","journal-title":"Scand J Gastroenterol Suppl"},{"key":"5005_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1152\/physrev.2001.81.3.1031","volume":"81","author":"DL Topping","year":"2001","unstructured":"Topping DL, Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81:1031\u20131064","journal-title":"Physiol Rev"},{"key":"5005_CR27","first-page":"15","volume":"5","author":"DL Topping","year":"1996","unstructured":"Topping DL (1996) Short-chain fatty acids produced by intestinal bacteria. Asia Pac J Clin Nutr 5:15\u201319","journal-title":"Asia Pac J Clin Nutr"},{"key":"5005_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ebiom.2018.03.030","volume":"30","author":"G Chen","year":"2018","unstructured":"Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W (2018) Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine 30:317\u2013325","journal-title":"EBioMedicine"},{"key":"5005_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1042\/CS20210778","volume":"136","author":"L Liang","year":"2022","unstructured":"Liang L, Liu L, Zhou W, Yang C, Mai G, Li H, Chen Y (2022) Gut microbiota-derived butyrate regulates gut mucus barrier repair by activating the macrophage\/WNT\/ERK signaling pathway. Clin Sci 136:291\u2013307","journal-title":"Clin Sci"},{"key":"5005_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/gutjnl-2016-313235","volume":"66","author":"V Pascal","year":"2017","unstructured":"Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K et al (2017) A microbial signature for Crohn\u2019s disease. Gut 66:813\u2013822","journal-title":"Gut"},{"key":"5005_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ibd.21894","volume":"18","author":"V De Preter","year":"2012","unstructured":"De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, Rutgeerts P, Verbeke K (2012) Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis 18:1127\u20131136","journal-title":"Inflamm Bowel Dis"},{"key":"5005_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.immuni.2013.12.007","volume":"40","author":"N Singh","year":"2014","unstructured":"Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, Thangaraju M, Prasad PD, Manicassamy S, Munn DH et al (2014) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40:128\u2013139","journal-title":"Immunity"},{"key":"5005_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","volume":"504","author":"N Arpaia","year":"2013","unstructured":"Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ et al (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:451\u2013455","journal-title":"Nature"},{"key":"5005_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569\u2013573","journal-title":"Science"},{"key":"5005_CR35","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1248\/bpb.b13-00312","volume":"36","author":"SU Lee","year":"2013","unstructured":"Lee SU, In HJ, Kwon MS, Park B, Jo M, Kim M-O, Cho S, Lee S, Lee H-J, Kwak YS et al (2013) \u03b2-Arrestin 2 mediates G protein-coupled receptor 43 signals to nuclear factor-\u03baB. Biol Pharm Bull 36:1754\u20131759","journal-title":"Biol Pharm Bull"},{"key":"5005_CR36","doi-asserted-by":"publisher","first-page":"e39743","DOI":"10.1371\/journal.pone.0039743","volume":"7","author":"W Chen","year":"2012","unstructured":"Chen W, Liu F, Ling Z, Tong X, Xiang C (2012) Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE 7:e39743","journal-title":"PLoS ONE"},{"key":"5005_CR37","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1073\/pnas.1322269111","volume":"111","author":"PV Chang","year":"2014","unstructured":"Chang PV, Hao L, Offermanns S, Medzhitov R (2014) The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111:2247\u20132252","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5005_CR38","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1038\/ncomms7734","volume":"6","author":"L Macia","year":"2015","unstructured":"Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, Maruya M, Ian McKenzie C, Hijikata A, Wong C et al (2015) Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun 6:6734","journal-title":"Nat Commun"},{"key":"5005_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbrc.2020.09.027","volume":"533","author":"W Xiu","year":"2020","unstructured":"Xiu W, Chen Q, Wang Z, Wang J, Zhou Z (2020) Microbiota-derived short chain fatty acid promotion of Amphiregulin expression by dendritic cells is regulated by GPR43 and Blimp-1. Biochem Biophys Res Commun 533:282\u2013288","journal-title":"Biochem Biophys Res Commun"},{"key":"5005_CR40","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/s41467-020-18262-6","volume":"11","author":"W Yang","year":"2020","unstructured":"Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, Sun J, Pan F, Zhou J, Zhang W et al (2020) Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun 11:4457","journal-title":"Nat Commun"},{"key":"5005_CR41","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.3390\/jcm9123941","volume":"9","author":"M Vernero","year":"2020","unstructured":"Vernero M, De Blasio F, Ribaldone DG, Bugianesi E, Pellicano R, Saracco GM, Astegiano M, Caviglia GP (2020) The usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study. J Clin Med 9:3941","journal-title":"J Clin Med"},{"key":"5005_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/nu14163283","volume":"14","author":"A Pietrzak","year":"2022","unstructured":"Pietrzak A, Banasiuk M, Szczepanik M, Borys-Iwanicka A, Pytrus T, Walkowiak J, Banaszkiewicz A (2022) Sodium butyrate effectiveness in children and adolescents with newly diagnosed inflammatory bowel diseases-randomized placebo-controlled multicenter trial. Nutrients 14:3283","journal-title":"Nutrients"},{"key":"5005_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.bjc.6600360","volume":"87","author":"AS Denton","year":"2002","unstructured":"Denton AS, Andreyev HJN, Forbes A, Maher EJ (2002) Systematic review for non-surgical interventions for the management of late radiation proctitis. Br J Cancer 87:134\u2013143","journal-title":"Br J Cancer"},{"key":"5005_CR44","doi-asserted-by":"crossref","unstructured":"Pinto A, Fidalgo P, Cravo M, Mid\u00f5es J, Chaves P, Rosa J, dos Anjos Brito M, Leit\u00e3o CN, (1999) Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis Colon Rectum 42:788\u2013795, discussion 795\u2013796.","DOI":"10.1007\/BF02236937"},{"issue":"12","key":"5005_CR45","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.cgh.2013.04.048","volume":"11","author":"AF Peery","year":"2013","unstructured":"Peery AF, Sandler RS (2013) Diverticular disease: reconsidering conventional wisdom. Clin Gastroenterol Hepatol 11(12):1532\u20131537. https:\/\/doi.org\/10.1016\/j.cgh.2013.04.048","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5005_CR46","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1097\/MCG.0000000000000611","volume":"50","author":"G Barbara","year":"2016","unstructured":"Barbara G, Cremon C, Barbaro MR, Bellacosa L, Stanghellini V (2016) Treatment of diverticular disease with aminosalicylates: the evidence. J Clin Gastroenterol 50:S60\u2013S63","journal-title":"J Clin Gastroenterol"},{"key":"5005_CR47","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1097\/MCG.0000000000000669","volume":"50","author":"M Picchio","year":"2016","unstructured":"Picchio M, Elisei W, Brandimarte G, Di Mario F, Malfertheiner P, Scarpignato C, Tursi A (2016) Mesalazine for the treatment of symptomatic uncomplicated diverticular disease of the colon and for primary prevention of diverticulitis: a systematic review of randomized clinical trials. J Clin Gastroenterol 50:S64\u2013S69","journal-title":"J Clin Gastroenterol"},{"key":"5005_CR48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2014.106","volume":"67","author":"F Calanni","year":"2014","unstructured":"Calanni F, Renzulli C, Barbanti M et al (2014) Rifaximin: beyond the traditional antibiotic activity. J Antibiot 67:667\u2013670","journal-title":"J Antibiot"},{"key":"5005_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00508-013-0447-7","volume":"126","author":"S Stallinger","year":"2014","unstructured":"Stallinger S, Eller N, H\u00f6genauer C (2014) Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. Wien Klin Wochenschr 126:9\u201314","journal-title":"Wien Klin Wochenschr"},{"key":"5005_CR50","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10151-015-1370-x","volume":"19","author":"GA Binda","year":"2015","unstructured":"Binda GA, Cuomo R, Laghi A, Nascimbeni R, Serventi A, Bellini D, Gervaz P, Annibale B (2015) Practice parameters for the treatment of colonic diverticular disease: Italian society of colon and rectal surgery (SICCR) guidelines. Tech Coloproctol 19:615\u2013626","journal-title":"Tech Coloproctol"},{"key":"5005_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.dld.2017.01.164","volume":"49","author":"R Cuomo","year":"2017","unstructured":"Cuomo R, Barbara G, Annibale B (2017) Rifaximin and diverticular disease: position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 49:595\u2013603","journal-title":"Dig Liver Dis"},{"key":"5005_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.21614\/sgo-24-5-233","volume":"24","author":"I Copaci","year":"2019","unstructured":"Copaci I, Constantinescu G, Mih\u0103il\u0103 M, Micu L, Franculescu-Bertea A (2019) Efficacy of rifaximin-\u03b1 vs dietary fiber on the evolution of uncomplicated colonic diverticular disease. Surg Gastroenterol Oncol 24:233\u2013240","journal-title":"Surg Gastroenterol Oncol"},{"key":"5005_CR53","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s10350-007-0226-5","volume":"50","author":"TA Salem","year":"2007","unstructured":"Salem TA, Molloy RG, O\u2019Dwyer PJ (2007) Prospective, five-year follow-up study of patients with symptomatic uncomplicated diverticular disease. Dis Colon Rectum 50:1460\u20131464","journal-title":"Dis Colon Rectum"},{"key":"5005_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00384-002-0396-5","volume":"18","author":"G Latella","year":"2003","unstructured":"Latella G, Pimpo M, Sottili S, Zippi M, Viscido A, Chiaramonte M, Frieri G (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Color Dis 18:55\u201362","journal-title":"Int J Color Dis"},{"key":"5005_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2036.2007.03562.x","volume":"27","author":"HM Hamer","year":"2008","unstructured":"Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27:104\u2013119","journal-title":"Aliment Pharmacol Ther"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-05005-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-05005-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-05005-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:12:30Z","timestamp":1760962350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-05005-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5005"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-05005-6","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.D.P. is the Scientific & Research Director at Pharmextracta SpA. A.B. is a Pharmextracta scientific adviser. The remaining authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}